Clinical Trials Browser

Expanded_access × ponatinib × Clear all

NCT01592136 2018-02-06

Expanded Access Program of Ponatinib

Approved for marketing

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive